The prevalence of affective disorders such as depression and anxiety is particularly high in patients with autoimmune diseases, including inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. A dysregulated immune response has been linked to the precipitation of depression in many patient populations. However, studies examining the extent to which the underlying skin disease inflammatory processes contribute to depression and a subsequent decline in quality of life are limited. The published literature over the past 5 years was reviewed for evidence of a relationship between depression and inflammatory processes in the context of skin pathology. The findings, particularly the evidence from interventional clinical trials of targeted anti-cytokine therapies, suggest that pro-inflammatory cytokines associated with several skin diseases may be causally linked with the coexistent depressive symptomology.

1.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al: The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984–991.
2.
Gupta MA, Gupta AK: Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4: 833–842.
3.
Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, et al: Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2014; 29: 1063–1070.
4.
Connor CJ, Liu V, Fiedorowicz JG: Exploring the physiological link between psoriasis and mood disorders. Dermatol Res Pract 2015; 2015: 1–11.
5.
Janse IC, Deckers IE, van der Maten AD, Evers AW, Boer J, van der Zee HH, et al: Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicenter cross-sectional study. Br J Dermatol 2017; 176: 1042–1047.
6.
Gooderham N: Atopic dermatitis, depression, and suicidality. J Cutan Med Surg 2017; 21: 237–242.
7.
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM: Psoriasis causes as much disability as other major medical diseases: J Am Acad Dermatol 1999; 41: 401–407.
8.
Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD: Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133: 97–103.
9.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD: Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015; 29: 371–376.
10.
Kirby JS, Butt M, Esmann S, Jemec GBE: Association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. JAMA Dermatol 2017; 153: 1263–1269.
11.
Nicholas MN, Gooderham MJ: Atopic dermatitis, depression, and suicidality. J Cutan Med Surg 2017; 21: 237–242.
12.
Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A: increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol 2018; 138: 52–57.
13.
Chi CC, Chen TH, Wang SH, Tung TH: Risk of suicidality in people with psoriasis: a systematic review and meta-analysis of cohort studies. Am J Clin Dermatol 2017; 18: 621–627.
14.
Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K: Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish nationwide registry study. J Invest Dermatol 2018; 138: 46–51.
15.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
16.
Rosenblat JD, Cha DS, Mansur RB, McIntyre RS: Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53: 23–34.
17.
Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P: Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25: 39–47.
18.
Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH: Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342–1345.
19.
Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al: Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268–275.
20.
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445–452.
21.
Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, et al: Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA 2014; 111: 16136–16141.
22.
Yirmiya R, Rimmerman N, Reshef R: Depression as a microglial disease. Trends Neurosci 2015; 38: 637–658.
23.
Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2017; 65: 1–10.
24.
Dantzer R, O’Connor JC, Lawson MA, Kelley KW: Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426–436.
25.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
26.
Sapolsky RM: Stress and the brain: individual variability and the inverted-U. Nat Neurosci 2015; 18: 1344–1346.
27.
Lee AL, Ogle WO, Sapolsky RM: Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 2002; 4: 117–128.
28.
Sartorius K, Emtestam L, Lapins J, Johansson O: Cutaneous PGP 9.5 distribution patterns in hidradenitis suppurativa. Arch Dermatol Res 2010; 302: 461–468.
29.
Buske-Kirschbaum A, Geiben A, Höllig H, Morschhäuser E, Hellhammer D: Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis. J Clin Endocrinol Metabol 2002; 87: 4245–4251.
30.
Quevedo ME, Slominski A, Pinto W, Wei E, Wortsman J: Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim 2001; 37: 50–54.
31.
Raison CL, Miller AH: Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13: 467–475.
32.
Fonseca JE, Santos MJ, Canhao H, Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538–542.
33.
Krishnadas R, Cavanagh J: Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012; 83: 495–502.
34.
Richards HL, Ray DW, Kirby B, Mason D, Plant D, Main CJ, Fortune DG, Griffiths CE: Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 2005; 153: 1114–1120.
35.
Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P: Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000; 143: 983–991.
36.
Von der Werth J, Jemec G: Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809–813.
37.
Marek-Jozefowicz L, Jaracz M, Placek W, Czajkowski R, Borkowska A: Cognitive impairment in patients with severe psoriasis. Postepy Dermatol Alergol 2017; 34: 120–125.
38.
Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, et al: Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology 2014; 228: 78–85.
39.
Colgecen E, Celikbilek A, Keskin DT: Cognitive impairment in patients with psoriasis: a cross-sectional study using the Montreal Cognitive Assessment. Am J Clin Dermatol 2016; 17: 413–419.
40.
Shlyankevich J, Chen AJ, Kim GE, Kimball AB: Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71: 1144–1150.
41.
Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al: Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology 2016; 232: 687–691.
42.
Fimmel S, Zouboulis CC: Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology 2010; 2: 9–16.
43.
Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ: Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679–691.
44.
Baurecht H, Hotze M, Brand S, Buning C, Cormican P, Corvin A, et al: Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet 2015; 96: 104–120.
45.
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al: Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336–349.
46.
Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF: How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 2013; 19: 822–824.
47.
Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB: The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133: 17–26.
48.
Towne JE, Sims JE: IL-36 in psoriasis. Curr Opin Pharmacol 2012; 12: 486–490.
49.
Matsunaga MC, Yamauchi PS: IL-4 and IL-13 inhibition in atopic dermatitis. J Drugs Dermatol 2016; 15: 925–929.
50.
Hoffman LK, Ghias MH, Garg A, Hamzavi IH, Alavi A, Lowes MA: Major gaps in understanding and treatment of hidradenitis suppurativa. Semin Cutan Med Surg 2017; 36: 86–92.
51.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35.
52.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al: Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457–465.
53.
Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P: The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812–818.
54.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al: Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348.
55.
Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 506–515.
56.
Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M: Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J 2016; 22:pii: 13030/qt38x5922j.
57.
Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J: Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry 2014; 71: 1381–1311.
58.
Hannestad J, DellaGioia N, Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36: 2452–2459.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.